Foghorn Therapeutics Inc.

We're looking forward to joining fellow industry leaders and researchers in targeted protein degradation (TPD) for Hanson Wade Group's 7th Annual TPD & Induced Proximity Summit. If you're attending, be sure to catch Foghorn CEO Adrian Gottschalk in a panel discussion about advancing programs through the clinic and pipeline management and hear our CSO Steven Bellon, PhD give a presentation on our selective CBP and EP300 degrader programs: https://bit.ly/3YD3NYs

We’re looking forward to the American Association of Pharmaceutical Scientists (AAPS) | aapscomms #PharmSci360 conference, where we’ll present two posters related to the development and preclinical data of long-acting injectables for delivery of targeted protein degraders. Learn more about the conference: https://bit.ly/3Y7ppLh

Our team recently celebrated the beginning of fall with a special company outing, where we enjoyed great food, fun, and games. #biotechnology #culture

Today, we announced that the first patient has been dosed with FHD-909 in the Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population. Read the announcement to learn more about FHD-909 and the Phase 1 trial for SMARCA4 mutated solid tumors: https://bit.ly/3NkA4NH

If you’re attending the Epigenetics Fusion Conferences be sure to catch the presentation from Danette Daniels, head of our protein degrader platform, to learn how we’re targeting proteins in the chromatin regulatory system with our therapeutic protein degraders. See the agenda: https://bit.ly/3zSPd5M #Epigen24

We’re thrilled to have Mike Garcia-Webb join our team as Vice President, Chief of Staff Research. Michael has more than 16 years of discovery, development, and commercial experience across multiple therapeutic areas, and we look forward to leveraging his expertise as we pioneer a new class of medicines to treat serious diseases. #drugdevelopment #biotechnology #oncology

We’re looking forward to presenting at the annual Discovery On Target 2024 conference. Check out the agenda to see research about current and emerging novel targets and technologies, and be sure to catch our presentations: https://bit.ly/4exvbfC #BostonDOT #biotechnology #innovation

We're looking forward to attending the BMO Oncology Summit next week in New York, NY. Read our announcement: https://bit.ly/3ZM4Hmx #biotechnology #oncology

Congratulations to our Foghorn team of scientists on the publication of their book chapter, “Chromatin Remodeling Complexes: Arising opportunities and challenges.” As part of the Royal Society of Chemistry Epigenetic Drug Discovery book, this chapter offers a comprehensive review of approaches to drugging remodeling complexes spanning inhibitors to degraders to protein interaction disruptors. With a focus on BAF, it explores the opportunities for potential treatments in various oncology indications and beyond. https://rsc.li/4duB4cO #innovation #cancerresearch #biotechnology

In honor of #BloodCancerAwarenessMonth, our team held a special bake sale to raise money for The Leukemia & Lymphoma Society New England’s #LightTheNight fundraiser. Thank you, team Foghorn!